SILO

Silo Pharma is a developmental-stage biopharma with no approved products and no real commercial engine. "Revenue" has been frozen at exactly $72.1K for four straight years (FY2022–FY2025) — this is not a business growing into its valuation, it is a licensing/pipeline story. Its four candidates (lead SPC-15 intranasal for PTSD/anxiety, SP-26 ketamine implant, plus preclinical SPC-14 and SPU-16) are all early-stage, and management concedes in the 10-K that "clinical testing is expensive and can take many years... its outcome is inherently uncertain. Failure can occur at any time." That is binary, unknowable risk, which by the rubric maps to avoid.

The cash math is the immediate problem. FY2025 operating cash flow was -$4.66M against just $4.75M of cash — roughly one year of runway. The 10-K is explicit: the company "will require additional financing," "will need additional capital," has "no history of profitable operations," and has "not yet achieved positive cash flow on a monthly basis during any fiscal year." It also warns raising capital "will be dilutive." That is a going-concern-style dependency on markets that may not cooperate. Dilution is not hypothetical: shares outstanding already jumped +215.9% YoY to 14.2M, so existing holders were heavily diluted even before the next raise. Oddly, the company also paid $1.0M for buybacks in FY2024 while burning cash and preparing to sell more stock — poor capital allocation for a company this fragile.